Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Average Drug Price Discrepancy Rate at 8.2%: Health Ministry
December 9, 2013
- PMDA Aims to Solidify Partnerships with Overseas Regulators via February Symposium
December 9, 2013
- MHLW to Make Additional Appeal for Applicants for Special Grants to Produce Vaccines for New Strains of Influenza
December 6, 2013
- MHLW Calls for Caution on ADRs Associated with Axitinib, Bevacizumab
December 6, 2013
- Revision of Notification on Advanced Healthcare Introduces New Rules for Anticancer Drugs
December 5, 2013
- Would Proposed New Rule for Repricing Long-Listed Drugs Create Winners and Losers? Bill Payers Opposed, Industry Watching Closely
December 5, 2013
- PAFSC’s First Committee Backs Japan’s 1st SGLT-2 Inhibitor
December 2, 2013
- 11 APIs/33 Products Including ComPlavin Added to NHI Price List
December 2, 2013
- PFSB Issues Notification Calling for Revisions of Package Inserts for Drugs Including Aricept, Cravit
December 2, 2013
- Toned-Down Proposal on “Precursor” Premium Still Leaves CSIMC Wary; 10% Tabled with Strings Attached
November 29, 2013
- New Proposals by Regulatory Reform Council Include Elimination of 14-Day Prescription Limit
November 29, 2013
- New Combination Drugs Containing Non-Innovative APIs Should Be Priced Based on Prices of Other APIs Contained: CSIMC Subcommittee
November 29, 2013
- CSIMC Bill Payer Rep Repeats Opposition to Replacing Special Price Cut for Off-Patent Drugs with New Rule
November 28, 2013
- Ministry Revises Plan to Set First Generic Prices, Suggests 50% or 60%
November 28, 2013
- MHLW Proposes to “Institutionalize” New Drug Premium; Equivocal Wording Draws Fire at CSIMC
November 28, 2013
- RMPs Required for Generics when RMPs Submitted for Original Products: Health Ministry
November 27, 2013
- Nearly 60% of Face-to-Face Consultations from July 2011 through September 2013 Involved Drugs: PMDA
November 26, 2013
- Subcommittee Agrees to Introduction of New Price Reduction Rule for Long-Listed Drugs Next Year; Will Continue to Discuss Details
November 22, 2013
- JGA President Opposes 50% Rule for Generics, CSIMC Subcommittee Members Disagree
November 21, 2013
- Upper House Passes Amended Pharmaceutical Affairs Law and Law to Ensure Safety of Regenerative Medicine
November 21, 2013
ページ
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…